Third Day, 28th May 2022
Theme 3: Car-T Cell Therapy and the New Rights
9.00. JOHN G GRIBBEN, MD, DSc, Gordon Hamilton Fairley Chair of Medical Oncology, University of London
Car-T Cell Therapy
John G Gribben MD DSc, Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew’s Hospital, Barts Cancer Institute, Queen Mary, University of London. Doctoral studies at University College London as the recipient of a Wellcome Trust Fellowship Award. Post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School. A founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.
10.00. ULRICH JÄGER, MD, Co-Chair of EMA´s Health Care, , Coordinator of the Austrian Car-T cell Network, Medical University Vienna
Rights related to patients/health care providers/industry/academia?
Ulrich Jäger is Professor of Internal Medicine in the Division of Hematology and Hemostaseology at the Medical University of Vienna. He served as president of the European Hematology Association from 2011 to 2013. He gained his professional experience at the Medical University of Vienna and at Washington University, St. Louis, Missouri. He is currently the co-chair of EMA´s Health Care Professional Working Party. Dr Jäger’s scientific interests focus on personalized precision medicine as well as CAR-T cell therapies. He is coordinating the Austrian CAR-T Cell Network which prepares treatment algorithms, recommendations and conducts real world data analysis for CAR-T Cell treatment in Austria. This Network is also used as a reference for payer and health care authority decisions.
11.00. GIAMPAOLO MERLINI, MD, Director of the Center for Research and Treatment of Systemic Amyloidosis
Discussing the Paper: CAR T-cell therapy roll-out in low-income and middle-income countries
Giampaolo Merlini is an MD, who works in translational and clinical research in the field of systemic amyloidosis. He has contributed to the development of effective therapies for these rare diseases and is interested in the patient’s access to novel drugs.
11.45. COMOLI PATRIZIA, MD, Director of the GMP Facility and Center for Advanced Cellular Therapies at the Fondazione IRCCS Policlinico S. Matteo, Pavia,
The challenge of expanding access to CAR T-cell therapy in middle- and low-income countries
Patrizia Comoli (MD) is the Director of the GMP Facility and Center for Advanced Cellular Therapies at the Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. She obtained her MD and Board Certification in Pediatrics from the University of Pavia, Italy, and proceeded to acquire expertise in Cell and Gene Therapy at St. Jude Childrens’ ResearchHospital, Memphis, USA. She served as senior group leader for programs of transplant immunology and management of viral complications and leukemia relapse following hematopoietic stem cell transplantation. She is currently contract professor of Pediatric Hematology and her research activity is focused on cellular therapy for pathogen-related disease and cancer, and on regenerative medicine.
12.25. RICHARD GRIMES, Former Director of Clinical Programmes, Charles University Prague and at Edinburgh Law School
Experimental learning: experiential learning in in the context of rights and Car-T-Cell Therapy: Exercise
‘Richard Grimes is a visiting professor at Charles University Prague and at Edinburgh Law School. He is a solicitor (England and Wales) was formerly Director of Clinical Programmes at the University of York and Professor of Pro Bono and Clinical Legal Education at the (then) College of Law. He is widely published in experiential learning and access to justice and has worked as a consultant for a wide range of governmental, regulatory and not for profit bodies.
13.30. Students’ Participation